Isofagomine in vivo effects in a neuronopathic gaucher disease mouse

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Sun, Ying ^a   Ran, Huimin ^a   Liou, Benjamin ^a   Quinn, Brian ^a   Zamzow, Matt ^a   Zhang, Wujuan ^a   Bielawski, Jacek ^b   Kitatani, Kazuyuki ^b,c   Setchell, Kenneth D R ^a   Hannun, Yusuf A ^b   Grabowski, Gregory A ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c TOTTORI UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CERAMIDE GLUCOSYLTRANSFERASE INHIBITOR; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUCOSYLCERAMIDE; GLUCOSYLSPHINGOSINE; ISOFAGOMINE TARTRATE; LACTOSYLCERAMIDE; SPHINGOSINE; SPHINGOSINE LACTOSIDE; SYNAPTOPHYSIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; GLYCOSIDASE; IMINOSUGAR; ISOFAGOMINE; MITOGEN ACTIVATED PROTEIN KINASE P38;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTROCYTOSIS; ATTENUATION; BRAIN LEVEL; CELL ACTIVATION; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MEGADOSE; ENZYME ACTIVITY; FEMALE; GAUCHER DISEASE; IN VIVO STUDY; LIFE EXTENSION; MALE; MICROGLIA; MOUSE; NERVE FIBER DEGENERATION; NONHUMAN; PHENOTYPE; TISSUE LEVEL; ANIMAL; DISEASE MODEL; DRUG ANTAGONISM; INFLAMMATION; METABOLISM; PHOSPHORYLATION;

MUS;

ANIMALS; DISEASE MODELS, ANIMAL; GAUCHER DISEASE; GLYCOSIDE HYDROLASES; IMINO PYRANOSES; INFLAMMATION; MICE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79955404357     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019037     Document Type: Article

References (39)

1. Grabowski GA, Petsko GA, Kolodny EH, (2010) Gaucher disease. In: Valle D, Beaudet A, Vogelstein B, Kinzler KW, Antonarakis SE et al, editors. The Online Metabolic and Molecular Bases of Inherited Diseases New York The McGraw-Hill Companies, Inc.
2. Gupta N, Oppenheim IM, Kauvar EF, Tayebi N, Sidransky E, (2010) Type 2 Gaucher disease: Phenotypic variation and genotypic heterogeneity. Blood Cells Mol Dis.
3. Weinreb NJ, Charrow J, Andersson HC, Kaplan P, Kolodny EH, et al. (2002) Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med 113: 112-119.
4. Wenstrup RJ, Kacena KA, Kaplan P, Pastores GM, Prakash-Cheng A, et al. (2007) Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease. J Bone Miner Res 22: 119-126.
5. Grabowski GA, Kacena K, Cole JA, Hollak CE, Zhang L, et al. (2009) Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1. Genet Med 11: 92-100.
6. Burrow TA, Cohen MB, Bokulic R, Deutsch G, Choudhary A, et al. (2007) Gaucher disease: progressive mesenteric and mediastinal lymphadenopathy despite enzyme therapy. J Pediatr 150: 202-206.
7. Radin NS, (1994) Rationales for cancer chemotherapy with PDMP, a specific inhibitor of glucosylceramide synthase. Mol Chem Neuropathol 21: 111-127.
8. Weinreb NJ, Barranger JA, Charrow J, Grabowski GA, Mankin HJ, et al. (2005) Guidance on the use of miglustat for treating patients with type 1 Gaucher disease. Am J Hematol 80: 223-229.
9. McEachern KA, Fung J, Komarnitsky S, Siegel CS, Chuang WL, et al. (2007) A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease. Mol Genet Metab 91: 259-267.
10. Marshall J, McEachern KA, Chuang WL, Hutto E, Siegel CS, et al. (2010) Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy. J Inherit Metab Dis 33: 281-289.
11. Lukina E, Watman N, Arreguin EA, Banikazemi M, Dragosky M, et al. (2010) A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. Blood 116: 893-899.
12. Fan JQ, (2008) A counterintuitive approach to treat enzyme deficiencies: use of enzyme inhibitors for restoring mutant enzyme activity. Biol Chem 389: 1-11.
13. Sawkar AR, Cheng WC, Beutler E, Wong CH, Balch WE, et al. (2002) Chemical chaperones increase the cellular activity of N370S beta-glucosidase: a therapeutic strategy for Gaucher disease. Proc Natl Acad Sci U S A 99: 15428-15433.
14. Mu TW, Fowler DM, Kelly JW, (2008) Partial restoration of mutant enzyme homeostasis in three distinct lysosomal storage disease cell lines by altering calcium homeostasis. PLoS Biol 6: e26.
15. Steet RA, Chung S, Wustman B, Powe A, Do H, et al. (2006) The iminosugar isofagomine increases the activity of N370S mutant acid beta-glucosidase in Gaucher fibroblasts by several mechanisms. Proc Natl Acad Sci U S A 103: 13813-13818.
16. Khanna R, Benjamin ER, Pellegrino L, Schilling A, Rigat BA, et al. (2010) The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of beta-glucosidase. FEBS J.
17. Sun Y, Liou B, Ran H, Skelton MR, Williams MT, et al. (2010) Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits. Hum Mol Genet 19: 1088-1097.
18. Zhang J, Shen B, Lin A, (2007) Novel strategies for inhibition of the p38 MAPK pathway. Trends Pharmacol Sci 28: 286-295.
19. Kitatani K, Sheldon K, Anelli V, Jenkins RW, Sun Y, et al. (2009) Acid beta-glucosidase 1 counteracts p38delta-dependent induction of interleukin-6: possible role for ceramide as an anti-inflammatory lipid. J Biol Chem 284: 12979-12988.
20. Lieberman RL, Wustman BA, Huertas P, Powe AC Jr, Pine CW, et al. (2007) Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease. Nat Chem Biol 3: 101-107.
21. Lieberman RL, D'Aquino JA, Ringe D, Petsko GA, (2009) Effects of pH and iminosugar pharmacological chaperones on lysosomal glycosidase structure and stability. Biochemistry 48: 4816-4827.
22. Xu YH, Sun Y, Barnes S, Grabowski GA, (2010) Comparative therapeutic effects of velaglucerase alfa and imiglucerase in a Gaucher disease mouse model. PLoS One 5: e10750.
23. Xu YH, Reboulet R, Quinn B, Huelsken J, Witte D, et al. (2008) Dependence of reversibility and progression of mouse neuronopathic Gaucher disease on acid beta-glucosidase residual activity levels. Mol Genet Metab.
24. Xu YH, Quinn B, Witte D, Grabowski GA, (2003) Viable mouse models of acid beta-glucosidase deficiency: the defect in Gaucher disease. Am J Pathol 163: 2093-2101.
25. Sun Y, Qi X, Grabowski GA, (2003) Saposin C is required for normal resistance of acid beta-glucosidase to proteolytic degradation. J Biol Chem 278: 31918-31923.
26. Sun Y, Ran H, Zamzow M, Kitatani K, Skelton MR, et al. (2010) Specific saposin C deficiency: CNS impairment and acid beta-glucosidase effects in the mouse. Hum Mol Genet 19: 634-647.
27. Jeyakumar M, Thomas R, Elliot-Smith E, Smith DA, van der Spoel AC, et al. (2003) Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis. Brain 126: 974-987.
28. Jeyakumar M, Smith DA, Williams IM, Borja MC, Neville DC, et al. (2004) NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin. Ann Neurol 56: 642-649.
29. Smith D, Wallom KL, Williams IM, Jeyakumar M, Platt FM, (2009) Beneficial effects of anti-inflammatory therapy in a mouse model of Niemann-Pick disease type C1. Neurobiol Dis 36: 242-251.
30. Luzi P, Abraham RM, Rafi MA, Curtis M, Hooper DC, et al. (2009) Effects of treatments on inflammatory and apoptotic markers in the CNS of mice with globoid cell leukodystrophy. Brain Res 1300: 146-158.
31. Munoz L, Ralay Ranaivo H, Roy SM, Hu W, Craft JM, et al. (2007) A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model. J Neuroinflammation 4: 21.
32. Klegeris A, Pelech S, Giasson BI, Maguire J, Zhang H, et al. (2008) Alpha-synuclein activates stress signaling protein kinases in THP-1 cells and microglia. Neurobiol Aging 29: 739-752.
33. Butters TD, Dwek RA, Platt FM, (2005) Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses. Glycobiology 15: 43R-52R.
34. Nishimura Y, (2009) Gem-diamine 1-N-iminosugars as versatile glycomimetics: synthesis, biological activity and therapeutic potential. J Antibiot (Tokyo) 62: 407-423.
35. Zhu Z, Zheng T, Homer RJ, Kim YK, Chen NY, et al. (2004) Acidic mammalian chitinase in asthmatic Th2 inflammation and IL-13 pathway activation. Science 304: 1678-1682.
36. Sun Y, Quinn B, Witte DP, Grabowski GA, (2005) Gaucher disease mouse models: point mutations at the acid {beta}-glucosidase locus combined with low-level prosaposin expression lead to disease variants. J Lipid Res 46: 2102-2113.
37. Kitatani K, Sheldon K, Rajagopalan V, Anelli V, Jenkins RW, et al. (2009) Involvement of acid beta-glucosidase 1 in the salvage pathway of ceramide formation. J Biol Chem 284: 12972-12978.
38. Xu YH, Ponce E, Sun Y, Leonova T, Bove K, et al. (1996) Turnover and distribution of intravenously administered mannose-terminated human acid beta-glucosidase in murine and human tissues. Pediatr Res 39: 313-322.
39. Sun Y, Witte DP, Ran H, Zamzow M, Barnes S, et al. (2008) Neurological deficits and glycosphingolipid accumulation in saposin B deficient mice. Hum Mol Genet 17: 2345-2356.